These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 30297804)

  • 21. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
    Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
    Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
    Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
    BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorylation of initiation factor 4E is resistant to SB203580 in cells expressing a drug-resistant mutant of stress-activated protein kinase 2a/p38.
    Morley SJ; Naegele S
    Cell Signal; 2003 Aug; 15(8):741-9. PubMed ID: 12781867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
    Liu Y; Sun L; Su X; Guo S
    Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pro-inflammatory cytokine release in keratinocytes is mediated through the MAPK signal-integrating kinases.
    Kjellerup RB; Kragballe K; Iversen L; Johansen C
    Exp Dermatol; 2008 Jun; 17(6):498-504. PubMed ID: 18081851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MNK1 inhibitor as an antiviral agent suppresses buffalopox virus protein synthesis.
    Kumar R; Khandelwal N; Chander Y; Riyesh T; Tripathi BN; Kashyap SK; Barua S; Maherchandani S; Kumar N
    Antiviral Res; 2018 Dec; 160():126-136. PubMed ID: 30393013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
    Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
    Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
    Liu Z; Li Y; Lv C; Wang L; Song H
    Biochem Biophys Res Commun; 2016 Sep; 478(2):893-9. PubMed ID: 27520370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.
    Shi Y; Frost P; Hoang B; Yang Y; Fukunaga R; Gera J; Lichtenstein A
    Oncogene; 2013 Jan; 32(2):190-7. PubMed ID: 22370634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction.
    Shveygert M; Kaiser C; Bradrick SS; Gromeier M
    Mol Cell Biol; 2010 Nov; 30(21):5160-7. PubMed ID: 20823271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of MNK Kinase-dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors.
    Pham TND; Kumar K; DeCant BT; Shang M; Munshi SZ; Matsangou M; Ebine K; Munshi HG
    Mol Cancer Ther; 2019 Feb; 18(2):235-244. PubMed ID: 30446586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
    Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
    Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a).
    Stead RL; Proud CG
    FEBS Lett; 2013 Aug; 587(16):2623-8. PubMed ID: 23831578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells.
    Eckerdt F; Beauchamp E; Bell J; Iqbal A; Su B; Fukunaga R; Lulla RR; Goldman S; Platanias LC
    Oncotarget; 2014 Sep; 5(18):8442-51. PubMed ID: 25193863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.
    Ramalingam S; Gediya L; Kwegyir-Afful AK; Ramamurthy VP; Purushottamachar P; Mbatia H; Njar VC
    Oncotarget; 2014 Jan; 5(2):530-43. PubMed ID: 24504069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
    Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
    Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
    Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
    Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mnk1 and 2 are dispensable for T cell development and activation but important for the pathogenesis of experimental autoimmune encephalomyelitis.
    Gorentla BK; Krishna S; Shin J; Inoue M; Shinohara ML; Grayson JM; Fukunaga R; Zhong XP
    J Immunol; 2013 Feb; 190(3):1026-37. PubMed ID: 23269249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway.
    Chen C; Cheng CD; Wu H; Wang ZW; Wang L; Jiang ZR; Wang AL; Hu C; Dong YF; Niu WX; Qi S; Qi ZP; Liu J; Wang WC; Niu CS; Liu QS
    Acta Pharmacol Sin; 2021 Jan; 42(1):108-114. PubMed ID: 32398685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.